ImmunityBio Inc is a biotechnology company focused on developing innovative immunotherapy treatments to harness the body's immune system in the fight against cancer and infectious diseases. The company specializes in the discovery and commercialization of novel therapies that aim to stimulate an immune response, with a particular emphasis on enhancing the effectiveness of existing cancer treatments. By leveraging cutting-edge research and technology, ImmunityBio is dedicated to improving patient outcomes and finding breakthrough solutions for complex medical challenges. Read More
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company’s supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen receptor (CAR) used in combination with rituximab (anti-CD20) for patients with Waldenström Non-Hodgkins lymphoma, a rare B-cell malignancy.
ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial in BCG-naïve non-muscle-invasive bladder cancer (NMIBC), QUILT-2.005. Enrollment has exceeded internal expectations and is now over 85% complete, with full enrollment of the planned study population anticipated by Q2 2026. Based on the current enrollment trajectory, ImmunityBio anticipates submitting a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) by year end 2026.
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending December 31, 2025. ImmunityBio reported preliminary net product revenue of approximately $38.3 million during the three-month period ending December 31, 2025, which represented an increase of 20% over the $31.8 million of net product revenue earned during the third quarter of 2025 and a 431% increase over the three-month period ended December 31, 2024. ImmunityBio continues to see increased sales momentum supporting a trend of increases quarter-over-quarter with a 54% quarter over quarter unit volume growth rate during FY 2025.
As capital rotates toward select U.S.-based innovation stories heading into early 2026, a group of small-cap names across regulated fintech, wireless infrastructure, immuno-oncology, and medical technology is drawing increased investor attention. High Roller Technologies (NYSE: ROLR), SurgePays (NASDAQ: SURG), ImmunityBio (NASDAQ: IBRX), and ENDRA Life Sciences (NASDAQ: NDRA) each represent distinct sector-driven catalysts that align with current macro themes, regulatory momentum, and platform-scale potential.
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA® (nogapendekin alfa inbakicept) for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy. This marks the first approval of the Company’s innovative treatment for this indication anywhere in the world, and the first approval for subcutaneous administration.
